Charles River Laboratories International, Inc.

New York Stock Exchange
Back to all articles
Somewhat Bullish +35

Charles River’s (CRL) Vaccine Push Meets A Bumpy Quarter

AI-generated analysis

📉 Charles River reported a GAAP loss of $0.03 per share in the second quarter, driven by a $63.7 million one-time charge from divesting its CDMO and Cell Solutions businesses.

💰 Revenue fell 2.7% year-over-year to $1.00 billion, with organic growth stagnating at just 0.1%, marking the best performance since 2023.

🚀 The Digital Services & Analytics (DSA) segment posted its highest net book-to-bill in nearly four years, prompting management to raise non-GAAP earnings guidance for 2026.

🤝 Charles River announced a collaboration with Medigen Vaccine Biologics Corp to utilize next-generation sequencing technology for an enterovirus vaccine program.

📈 Manufacturing segment non-GAAP operating margins expanded significantly to 37.8% from 32.8% a year earlier.

💸 The company executed share buybacks, spending $300 million on 1.7 million shares in the first half of the year with $700 million remaining authorized.

📉 Research Models and Services revenue declined 1.8% as demand for small research models weakened in North America.

🏦 Hedge fund ownership increased to 47 from 43, indicating growing institutional interest despite a forward P/E of 22.47.

⚖️ Short sellers maintain a 6.14% short interest, reflecting skepticism about the company's transition costs versus operational progress.

Bullish Signals
  • Charles River raised non-GAAP earnings guidance for 2026 following the DSA segment's highest net book-to-bill in nearly four years.
  • The Manufacturing segment achieved a significant expansion in non-GAAP operating margins, climbing to 37.8% from 32.8% year-over-year.
  • Charles River successfully leveraged its acquired Pathoquest technology and AI-enabled digital pathology tools to secure a new collaboration with Medigen Vaccine Biologics Corp.
  • The company continues an active share repurchase program, having spent $300 million in the first half of the year while maintaining $700 million in remaining authorization.
Risk Factors
  • Charles River recorded a GAAP loss of $0.03 per share due to a $63.7 million charge from divesting its CDMO and Cell Solutions businesses.
  • Total revenue declined 2.7% year-over-year to $1.00 billion, with organic growth remaining sluggish at just 0.1%.
  • The Research Models and Services segment revenue slid 1.8% due to weakening demand for small research models in North America.
Full Analysis
Charles River Laboratories (CRL) reported a mixed second quarter characterized by a GAAP loss of $0.03 per share and a revenue decline of 2.7% year-over-year to $1.00 billion. The company posted the loss primarily due to a $63.7 million charge associated with divesting its CDMO and Cell Solutions businesses, as well as certain European Discovery Services sites. Despite these headline numbers, management raised non-GAAP earnings guidance for 2026, citing strong performance in its Digital Services & Analytics (DSA) segment. The DSA segment achieved its highest net book-to-bill ratio in nearly four years, driven by a collaboration with Medigen Vaccine Biologics Corp to apply next-generation sequencing technology to an enterovirus vaccine program. This partnership leverages Charles River's acquired Pathoquest capabilities and aligns with broader efforts to integrate AI-enabled digital pathology tools to speed up study turnarounds. The Manufacturing segment also showed resilience, with non-GAAP operating margins climbing to 37.8% from the prior year. Investors are weighing two distinct narratives: a strategic transition involving portfolio cleanup and expansion into new testing corners versus ongoing operational headwinds in Research Models and Services. While organic growth remained sluggish at 0.1%, the company continues its share buyback program, having spent $300 million in the first half of the year with $700 million remaining on authorization. Institutional interest has increased slightly with hedge fund holdings rising to 47, though short interest remains elevated at 6.14%.